2025-2026 Regular Session • Maine Legislature
LD538
Legislative Summary
An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Demographic Impact
Overall analysis of equity impact
80% Positive
Medium ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
2/11/2025
Committee on Health Coverage, Insurance and Financial Services suggested and ordered printed.
House of Representatives
2/11/2025
The Bill was REFERRED to the Committee on HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES.
House of Representatives
2/11/2025
Sent for concurrence. ORDERED SENT FORTHWITH.
House of Representatives
2/11/2025
The Bill was REFERRED to the Committee on HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES in concurrence
Senate
3/21/2025
Carried over, in the same posture, to the next special or regular session of the 132nd Legislature, pursuant to Joint Order SP 519.
House of Representatives
3/26/2025
Work Session Held
Joint Conference
3/26/2025
Voted: Divided Report
Joint Conference
Status Information
Current Status
Introduced(2/11/2025)
Chamber
Joint Conference
